14 August 2018
Visiongain’ has launched a new pharma report Global Diabetes Drugs Market 2017-2027:
Insulin and Insulin Analogues, DPP-4 Inhibitors, Biguanides, GLP-1 Agonists, Alpha-glucosidases, SGLT-2 Inhibitors, Sulfonylureas and Others
The IDF (International Diabetes Federation) predicts that by 2035, the global number of diabetics will reach over 582 million. While the market associated with type 1 diabetes will grow in line with population rate, the type 2 diabetes market will expand much more rapidly due to the aging of the general population, poor dietary habits and sedentary lifestyles, the latter two of which can be attributed to a growing urbanised and westernised population.
As with most disease medications, the diabetes drug industry is prone to generic competition. Despite this, the market still attracts new interest from drug firms, giving rise to an influx of new diabetes therapies. Continued research in this area will either lead to the development of a drug that is a slight modification on a current existing class of diabetes drug, or will uncover a new molecular target entirely. Most of the drugs currently in development are modifications and improvements to existing therapies, such as longer-acting insulins and new DPP-4 inhibitors.
The lead analyst of the report commented “Owing to the growing incidence of diabetes worldwide, especially in the Middle East, the Western Pacific region and Asia, there continues to be a tremendous need for newer anti-diabetic treatments with improved efficacy and safety, which translates to significant opportunities for drug manufacturers operating in this potentially lucrative market.
Moreover, as obesity is closely related to type 2 diabetes, medications that target long-term weight reduction and those that treat co-morbid conditions, are in demand. Consequently, many researchers are currently focused on developing diabetes therapies that can tackle multiple complications that follow the disease, particularly obesity and heart-related illnesses.”
Leading companies featured in the report include Novo Nordisk, Sanofi, Merck (MSD), Eli Lilly
Boehringer Ingelheim, Novartis, AstraZeneca, Takeda and other leading companies currently marketing or developing diabetes drugs.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to email@example.com or call her on +44 (0) 207 336 6100
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-to-business reports cusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
The 431-page report provides clear detailed insight into the generic drugs market. Discover the key drivers and challenges affecting the market.
03 July 2020
Where is the Clinical Workflow Solutions market heading? If you are involved in this sector you must read this newly updated report. Visiongain’s report shows you the potential revenues streams to 2030, assessing data, trends, opportunities and business prospects there.
03 July 2020
With the growing burden of rare diseases around the world, there has been a rise and advancement in the therapy development of these types of diseases. While the fact remains that over 90% of these diseases lack approval for treatment and the total number of terminal rare diseases to receive the first treatment every year remains low.
01 July 2020
The market growth is attributed to the growing adoption of big data and AI in data management and monitoring of clinical information in health care.